IDSA 2011: Capsaicin Patch Reduces Pain Due to HIV-Associated Neuropathy
- Details
- Category: Mitochondrial & Neuropathy
- Published on Friday, 04 November 2011 00:00
- Written by Liz Highleyman
A patch containing 8% capsaicin -- a compound derived from chili peppers -- significantly relieved the pain of nerve damage related to HIV or its treatment, investigators reported at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) last month in Boston.
IDSA 2011: Tenofovir Not Linked to Increased Kidney Risk in HIV+ Veterans Study
- Details
- Category: Liver, Kidney & Bone Toxicity
- Published on Friday, 04 November 2011 00:00
- Written by Liz Highleyman
Use of tenofovir (Viread, also in the Truvada and Atripla coformulations) was not associated with a higher risk of kidney toxicity compared with other antiretroviral agents, according to a study presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) last month in Boston.
IDSA 2011: CD4 Cell Regeneration Is Impaired in HIV Elite Controllers
- Details
- Category: HIV Basic Science
- Published on Tuesday, 25 October 2011 00:00
- Written by Liz Highleyman
Elite controllers -- the small proportion of HIV positive people who maintain undetectable viral load without antiretroviral therapy (ART) -- may still experience CD4 T-cell depletion and eventual disease progression due to inadequate regeneration of naive T-cells, according to findings presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) this week in Boston.
IDSA 2011: Heart Problems Are Common Among People with HIV, but Largely Related to Modifiable Risk Factors
- Details
- Category: Cardiovascular Disease
- Published on Tuesday, 01 November 2011 00:00
- Written by Liz Highleyman
Structural and functional cardiac abnormalities were found in more than half of an HIV positive cohort in Washington, DC, according to a report at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) last month in Boston. Heart problems were often related to modifiable factors such as obesity and diabetes, suggesting that lifestyle changes may lower the risk.
IDSA 2011: Boceprevir Increases Hepatitis C Treatment Response for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
- Written by Liz Highleyman
The recently approved hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis) added to pegylated interferon/ribavirin significantly improved the likelihood of virological response at week 24 in HIV/HCV coinfected patients, according to a late-breaker presentation at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) in Boston.
Web Design and Development by